TY - JOUR
T1 - Ongoing developments in sporadic inclusion body myositis
AU - Machado, Pedro M.
AU - Ahmed, Mhoriam
AU - Brady, Stefen
AU - Gang, Qiang
AU - Healy, Estelle
AU - Morrow, Jasper M.
AU - Wallace, Amanda C.
AU - Dewar, Liz
AU - Ramdharry, Gita
AU - Parton, Matthew
AU - Holton, Janice L.
AU - Houlden, Henry
AU - Greensmith, Linda
AU - Hanna, Michael G.
PY - 2014
Y1 - 2014
N2 - Sporadic inclusion body myositis (IBM) is an acquired muscle disorder associated with ageing, for which there is no effective treatment. Ongoing developments include: genetic studies that may provide insights regarding the pathogenesis of IBM, improved histopathological markers, the description of a new IBM autoantibody, scrutiny of the diagnostic utility of clinical features and biomarkers, the refinement of diagnostic criteria, the emerging use of MRI as a diagnostic and monitoring tool, and new pathogenic insights that have led to novel therapeutic approaches being trialled for IBM, including treatments with the objective of restoring protein homeostasis and myostatin blockers. The effect of exercise in IBM continues to be investigated. However, despite these ongoing developments, the aetiopathogenesis of IBM remains uncertain. A translational and multidisciplinary collaborative approach is critical to improve the diagnosis, treatment, and care of patients with IBM.
AB - Sporadic inclusion body myositis (IBM) is an acquired muscle disorder associated with ageing, for which there is no effective treatment. Ongoing developments include: genetic studies that may provide insights regarding the pathogenesis of IBM, improved histopathological markers, the description of a new IBM autoantibody, scrutiny of the diagnostic utility of clinical features and biomarkers, the refinement of diagnostic criteria, the emerging use of MRI as a diagnostic and monitoring tool, and new pathogenic insights that have led to novel therapeutic approaches being trialled for IBM, including treatments with the objective of restoring protein homeostasis and myostatin blockers. The effect of exercise in IBM continues to be investigated. However, despite these ongoing developments, the aetiopathogenesis of IBM remains uncertain. A translational and multidisciplinary collaborative approach is critical to improve the diagnosis, treatment, and care of patients with IBM.
KW - Allied health professions and studies
UR - http://www.ncbi.nlm.nih.gov/pubmed/25399751
M3 - Article
C2 - 25399751
SN - 1523-3774
VL - 16
JO - Current Rheumatology Reports
JF - Current Rheumatology Reports
IS - 477
ER -